During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Maximilian Merz, Leipzig University, Leipzig, DE. We asked, for a triple-class refractory patient entering 4L therapy, how would you sequence BCMA×CD3 (B-cell maturation antigen) and GPRC5D×CD3 (G protein-coupled receptor family C group 5 member D) bispecifics?

In this video interview, Maximilian Merz discusses approved BCMA- and GPRC5D-targeted bispecific antibodies elranatamab, teclistamab, and talquetamab. He outlines the adverse events and side effects related to each class of bispecific antibody, including the risk of infection and their impact on activities of daily living. Merz highlights individual patient factors, including lifestyle and hobbies, to determine an individualized treatment plan to maintain quality of life.